Dare Bioscience (DARE) Current Deferred Revenue (2016 - 2023)

Dare Bioscience's (DARE) quarterly Current Deferred Revenue came in at $205206.0 in Q3 2023, down 91.79% on a QoQ basis from $2.5 million in Q2 2017.

Dare Bioscience (DARE) Current Deferred Revenue (2016 - 2023) Analysis & Trends

Dare Bioscience (DARE) has 3 years of Current Deferred Revenue data on file, last reported at $205206.0 in Q3 2023.

Quarterly Current Deferred Revenue changed N/A year-over-year to $205206.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $205206.0 (changed N/A YoY) and the FY2016 annual result came in at $2.5 million, changed N/A from the prior year.
Current Deferred Revenue slipped to $205206.0 in Q3 2023, from $2.5 million in the prior quarter.
In the past five years, Current Deferred Revenue ranged from a high of $205206.0 in Q3 2023 to a low of $205206.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.03 Bn	131.18 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.64 Bn	77.64 Bn	3.93 Bn
3	Argenx Se	64.93 Bn	59.75 Bn	1.37 Bn
4	Moderna	57.93 Bn	52.80 Bn	52.00 Mn
5	BeOne Medicines	41.95 Bn	36.86 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.51 Bn	28.20 Bn	992.69 Mn
7	BioNTech SE	28.00 Bn	9.60 Bn	668.28 Mn
8	Insmed	27.42 Bn	26.26 Bn	358.27 Mn
9	Royalty Pharma	27.29 Bn	26.45 Bn	-
10	Dare Bioscience	12.35 Mn	-270,944.87	-132,343.00

Download Data